Vincerx Pharma, Inc.
VINC · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | 50% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -800.1% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -748.5% | – | – |
| EPS Diluted | -0.96 | 4.22 | -1.41 | -0.32 |
| % Growth | -122.7% | 399.3% | -340.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |